Name | delphinidin 3-O-β-D-sambubioside |
---|---|
Synonyms |
delphinidin 3-O-beta-D-sambubioside
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3-chromeniumyl 6-O-β-D-x ylopyranosyl-β-D-glucopyranoside chloride |
Description | Delphinidin-3-sambubioside (Dp3‐Sam) chloride is an anthocyanin that has orally active anti-inflammatory activity. Delphinidin-3-sambubioside chloride inhibits LPS-induced inflammatory factors release. Delphinidin-3-sambubioside chloride also alleviates hepatic lipid accumulation in HFD rats. Delphinidin-3-sambubioside chloride can be isolated from Hibiscus sabdariffa L.[1][3]. |
---|---|
Related Catalog | |
In Vitro | Delphinidin-3-sambubioside chloride (50-200 μM, 30 min) inhibits LPS-induced iNOS expression in RAW264.7 cells[1]. Delphinidin-3-sambubioside chloride (50-200 μM, 30 min) suppresses the phosphorylation of ERK1/2 and MEK1/2 in RAW264.7 cells[1]. Delphinidin-3-sambubioside chloride (50-200 μM, 30 min) downregulates NF-κB signaling pathway in RAW264.7 cells[1]. Delphinidin-3-sambubioside chloride (24 h) inhibits HL-60 cells proliferation by inducing apoptosis, with an IC50 of 75 μM[2]. Delphinidin-3-sambubioside chloride (100-200 µg/mL, 24 h) decreases intracellular TG levels and lipid accumulation in oleic acid-treated HepG2 cells[2]. Western Blot Analysis[1] Cell Line: RAW264.7 cells Concentration: 50, 100, 200 μM Incubation Time: 30 min Result: Suppressed the degradation of IκB, and the phosphorylation of p65. |
In Vivo | Delphinidin-3-sambubioside chloride (15 μmol/kg, i.p.) inhibits mouse paw edema induced by LPS[1]. Delphinidin-3-sambubioside chloride (30 mg/kg body, oral gavage, daily for eight weeks) decreases lipid accumulation in HFD rats[3]. Animal Model: Delphinidin-3-sambubioside chloride (15 μmol/kg, i.p.) 抑制 LPS 诱导的小鼠爪水肿[1]. Delphinidin-3-sambubioside chloride (30 mg/kg body,灌胃,每日一次,持续八周) 减少 HFD 大鼠的脂质积累[3]。 Dosage: 15 μmol/kg Administration: Intraperitoneal injection (i.p.), for 4 days. Result: Reduced the LPS-induced paw thickness. Decreased the edema by 89.3%. Decreased the levels of LPS induced serum IL-6, MCP-1 and TNF-α. Animal Model: HFD-fed rats[3] Dosage: 30 mg/kg Administration: Oral gavage, daily for eight weeks. Result: Reduced the body weight gain, visceral fat, and abdominal fat and decreased hepatic lipid deposits. |
References |
Molecular Formula | C26H29ClO16 |
---|---|
Molecular Weight | 632.95200 |
Exact Mass | 632.11400 |
PSA | 275.42000 |
Storage condition | 20°C |